Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Mavissakalian

Allergy & Immunology Tonawanda, NY Doctor of Osteopathy

NPI 1790028397 CMS profile 5697404

2540 Sheridan Dr, Tonawanda, NY 14150

Open in the dashboard

General payments

$12,903

477 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Mavissakalian of Tonawanda, NY is reported in the CMS Open Payments database as having received $12,903 across 477 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,437 70
2024 General $2,302 109
2023 General $2,176 96
2022 General $1,344 55
2021 General $1,416 45
2020 General $942 39
2019 General $3,285 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Mavissakalian
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Matthew Mavissakalian were reported at $1,437. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Matthew Mavissakalian Allergy & Immunology median Middle half National median
2019 $3,285 $594 $163–$1,512 $163
2020 $942 $426 $106–$1,233 $114
2021 $1,416 $638 $157–$1,708 $132
2022 $1,344 $790 $205–$1,961 $149
2023 $2,176 $852 $220–$2,147 $160
2024 $2,302 $865 $203–$2,267 $164
2025 $1,437 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $3,434 74 payments
  2. Regeneron Healthcare Solutions, Inc. $1,403 83 payments
  3. GlaxoSmithKline, LLC. $1,362 73 payments
  4. AstraZeneca Pharmaceuticals LP $1,015 40 payments
  5. CSL Behring $609 14 payments
  6. OptiNose US, Inc. $494 12 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $470 15 payments
  8. Pfizer Inc. $443 24 payments
  9. Genentech USA, Inc. $434 14 payments
  10. Amgen Inc. $408 13 payments
  11. Other $2,830 115 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,462 472 payments
  2. Consulting Fee $1,316 1 payment
  3. Education $100 3 payments
  4. Honoraria $25 1 payment
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $2,077 97 payments
  2. DUPIXENT Immunology $1,663 18 payments
  3. DUPIXENT Inflammation And Immunology $1,212 64 payments
  4. NUCALA $707 35 payments
  5. Hizentra $559 12 payments
  6. Xhance $494 12 payments
  7. TRELEGY ELLIPTA $375 23 payments
  8. Odactra $371 14 payments
  9. FASENRA $332 15 payments
  10. AIRSUPRA $324 9 payments
  11. Other $5,927 262 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,233

Median for Allergy/ Immunology: 449

Drug cost

$464,103

Median for Allergy/ Immunology: $169,700

Branded share of claims

50%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 53 $210,740
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 77 $56,358
Dupixent Syringe Dupilumab Brand 11 $49,543
Xolair Omalizumab Brand 11 $29,052
Qvar Redihaler Beclomethasone Dipropionate Brand 45 $14,785
Spiriva Respimat Tiotropium Bromide Brand 19 $11,632
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 16 $11,006
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 66 $10,985
Symbicort Budesonide/Formoterol Fumarate Brand 34 $9,811
Epinephrine Generic 24 $6,275

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$12,649

Medicare's payments for the services billed

Medicare patients

96

Average age 67

Services billed

778

68 women, 28 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 52%
Depression 21%
Chronic kidney disease 19%
Ischemic heart disease 16%
Diabetes 15%
COPD 15%
Osteoporosis 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $482
  • GENZYME CORPORATION $327
$808 64 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $229
$229 — —
NUCALA
  • GlaxoSmithKline, LLC. $184
$184 — —
ACTIMMUNE
  • Amgen Inc. $152
$152 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $106
$106 77 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

477 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record